Bristol-Myers Squibb Company (USD) Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Bristol-Myers Squibb Company (USD) Active

Route 206 & Province Line Road, Princeton, NJ, US, 08543

Stock Price USD

Price Change

Last Dividend USD

B+

Latest Rating

BMY's stock peer is CI (Cigna Corporation)

BMY's stock peer is CVS (CVS Health Corp.)

BMY's stock peer is ELV (Elevance Health Inc.)

BMY's stock peer is HCA (HCA Healthcare, Inc.)

BMY's stock peer is MCK (McKesson Corporation)

BMY's stock peer is VRTX (Vertex Pharmaceuticals Incorporated)

Healthcare Drug Manufacturers - General

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

100%

Dcf Rating

100%

Return On Equity

100%

Return On Assets

20%

Debt To Equity

40%

Price To Earnings

20%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2026-07-02	2026-08-03	0.63	4.36 %	Quarterly
2026-04-02	2026-05-01	0.63	4.19 %	Quarterly
2026-01-02	2026-02-02	0.63	4.66 %	Quarterly
2025-10-03	2025-11-03	0.62	5.46 %	Quarterly
2025-07-03	2025-08-01	0.62	5.24 %	Quarterly
2025-04-04	2025-05-01	0.62	4.41 %	Quarterly
2025-01-03	2025-02-03	0.62	4.28 %	Quarterly
2024-10-04	2024-11-01	0.60	4.45 %	Quarterly
2024-07-05	2024-08-01	0.60	5.98 %	Quarterly
2024-04-05	2024-05-01	0.60	4.55 %	Quarterly
2024-01-05	2024-02-01	0.60	4.44 %	Quarterly
2023-10-06	2023-11-01	0.57	4.04 %	Quarterly
2023-07-07	2023-08-01	0.57	3.55 %	Quarterly
2023-04-10	2023-05-01	0.57	3.14 %	Quarterly
2023-01-06	2023-02-01	0.57	3.05 %	Quarterly
2022-10-07	2022-11-01	0.54	3.08 %	Quarterly
2022-07-01	2022-08-01	0.54	2.74 %	Quarterly
2022-04-01	2022-05-02	0.54	2.82 %	Quarterly
2022-01-07	2022-02-01	0.54	3.27 %	Quarterly
2021-10-01	2021-11-01	0.49	3.31 %	Quarterly
2021-07-02	2021-08-02	0.49	2.88 %	Quarterly
2021-04-01	2021-05-03	0.49	2.98 %	Quarterly
2021-01-04	2021-02-01	0.49	2.97 %	Quarterly
2020-10-02	2020-11-02	0.45	3.01 %	Quarterly
2020-07-06	2020-08-03	0.45	2.98 %	Quarterly
2020-04-03	2020-05-01	0.45	3.12 %	Quarterly
2020-01-03	2020-02-03	0.45	2.65 %	Quarterly
2019-10-04	2019-11-01	0.41	3.31 %	Quarterly
2019-07-05	2019-08-01	0.41	3.50 %	Quarterly
2019-04-05	2019-05-01	0.41	3.47 %	Quarterly
2019-01-04	2019-02-01	0.41	3.57 %	Quarterly
2018-10-05	2018-11-01	0.40	2.57 %	Quarterly
2018-07-06	2018-08-01	0.40	2.84 %	Quarterly
2018-04-06	2018-05-01	0.40	2.54 %	Quarterly
2018-01-05	2018-02-01	0.40	2.54 %	Quarterly
2017-10-06	2017-11-01	0.39	2.45 %	Quarterly
2017-07-07	2017-08-01	0.39	2.75 %	Quarterly
2017-04-07	2017-05-01	0.39	2.90 %	Quarterly
2017-01-06	2017-02-01	0.39	2.59 %	Quarterly
2016-10-07	2016-11-01	0.38	2.77 %	Quarterly
2016-07-01	2016-08-01	0.38	2.07 %	Quarterly
2016-04-01	2016-05-02	0.38	2.36 %	Quarterly
2016-01-04	2016-02-01	0.38	2.14 %	Quarterly
2015-10-02	2015-11-02	0.37	2.50 %	Quarterly
2015-07-06	2015-08-03	0.37	2.17 %	Quarterly
2015-04-06	2015-05-01	0.37	2.30 %	Quarterly
2015-01-02	2015-02-02	0.37	2.44 %	Quarterly
2014-10-03	2014-11-03	0.36	2.85 %	Quarterly
2014-07-03	2014-08-01	0.36	2.97 %	Quarterly
2014-04-04	2014-05-01	0.36	2.75 %	Quarterly
2014-01-03	2014-02-03	0.36	2.65 %	Quarterly
2013-10-04	2013-11-01	0.35	2.98 %	Quarterly
2013-07-05	2013-08-01	0.35	3.16 %	Quarterly
2013-04-05	2013-05-01	0.35	3.36 %	Quarterly
2013-01-04	2013-02-01	0.35	4.19 %	Quarterly
2012-10-05	2012-11-01	0.34	4.05 %	Quarterly
2012-07-06	2012-08-01	0.34	3.87 %	Quarterly
2012-04-05	2012-05-01	0.34	3.96 %	Quarterly
2012-01-06	2012-02-01	0.34	3.87 %	Quarterly
2011-10-11	2011-11-01	0.33	4.07 %	Quarterly
2011-07-01	2011-08-01	0.33	4.59 %	Quarterly
2011-04-01	2011-05-02	0.33	4.91 %	Quarterly
2011-01-07	2011-02-01	0.33	4.95 %	Quarterly
2010-10-01	2010-11-01	0.32	4.68 %	Quarterly
2010-07-02	2010-08-02	0.32	5.09 %	Quarterly
2010-04-04	2010-05-03	0.32	4.71 %	Quarterly
2010-01-04	2010-02-01	0.32	4.88 %	Quarterly
2009-10-02	2009-11-02	0.31	5.51 %	Quarterly
2009-07-06	2009-08-03	0.31	6.13 %	Quarterly
2009-04-03	2009-05-01	0.31	5.64 %	Quarterly
2009-01-02	2009-02-02	0.31	5.42 %	Quarterly
2008-10-03	2008-11-03	0.31	5.96 %	Quarterly
2008-07-07	2008-08-01	0.31	5.88 %	Quarterly
2008-04-04	2008-05-01	0.31	5.45 %	Quarterly
2008-01-04	2008-02-01	0.31	4.40 %	Quarterly
2007-10-05	2007-11-01	0.28	3.77 %	Quarterly
2007-07-06	2007-08-01	0.28	3.53 %	Quarterly
2007-04-06	2007-05-01	0.28	4.07 %	Quarterly
2007-01-05	2007-02-01	0.28	4.25 %	Quarterly
2006-10-06	2006-11-01	0.28	4.55 %	Quarterly
2006-07-07	2006-08-01	0.28	4.44 %	Quarterly
2006-04-07	2006-05-01	0.28	4.56 %	Quarterly
2006-01-06	2006-02-01	0.28	4.95 %	Quarterly
2005-10-07	2005-11-01	0.28	4.83 %	Quarterly
2005-07-01	2005-08-01	0.28	4.44 %	Quarterly
2005-04-01	2005-05-02	0.28	4.39 %	Quarterly
2005-01-07	2005-02-01	0.28	4.52 %	Quarterly
2004-10-01	2004-11-01	0.28	4.69 %	Quarterly
2004-07-02	2004-08-02	0.28	4.57 %	Quarterly
2004-04-02	2004-05-03	0.28	4.62 %	Quarterly
2004-01-02	2004-02-02	0.28	3.94 %	Quarterly
2003-10-03	2003-11-03	0.28	4.30 %	Quarterly
2003-07-03	2003-08-01	0.28	4.12 %	Quarterly
2003-04-04	2003-05-01	0.28	5.10 %	Quarterly
2003-01-03	2003-02-01	0.28	4.84 %	Quarterly
2002-10-04	2002-11-01	0.28	4.84 %	Quarterly
2002-07-05	2002-08-01	0.28	4.57 %	Quarterly
2002-04-05	2002-05-01	0.28	2.91 %	Quarterly
2002-01-04	2002-02-01	0.28	2.12 %	Quarterly
2001-10-05	2001-11-01	0.28	1.87 %	Quarterly
2001-07-06	2001-08-01	0.28	1.99 %	Quarterly
2001-04-06	2001-05-01	0.28	1.84 %	Quarterly
2001-01-05	2001-02-01	0.28	1.51 %	Quarterly
2000-10-06	2000-11-01	0.24	1.76 %	Quarterly
2000-07-07	2000-08-01	0.24	1.61 %	Quarterly
2000-04-07	2000-05-01	0.24	1.43 %	Quarterly
2000-01-07	2000-02-01	0.24	1.51 %	Quarterly
1999-10-01	1999-11-01	0.21	1.31 %	Quarterly
1999-07-02	1999-08-01	0.21	1.19 %	Quarterly
1999-04-02	1999-05-01	0.21	1.27 %	Quarterly
1999-01-08	1999-02-01	0.43	1.22 %	Quarterly
1998-10-02	1998-11-01	0.39	1.50 %	Quarterly
1998-07-03	1998-08-01	0.39	1.35 %	Quarterly
1998-04-03	1998-05-01	0.39	1.45 %	Quarterly
1998-01-02	1998-02-01	0.39	1.61 %	Quarterly
1997-10-03	1997-11-01	0.38	1.84 %	Quarterly
1997-07-03	1997-08-01	0.38	1.87 %	Quarterly
1997-04-04	1997-05-01	0.38	2.49 %	Quarterly
1997-01-03	1997-02-01	0.76	2.76 %	Quarterly
1996-10-04	1996-11-01	0.75	3.08 %	Quarterly
1996-07-05	1996-08-01	0.75	3.34 %	Quarterly
1996-04-05	1996-05-01	0.75	3.45 %	Quarterly
1996-01-05	1996-02-01	0.75	3.54 %	Quarterly
1995-10-06	1995-11-01	0.74	3.89 %	Quarterly
1995-07-07	1995-08-01	0.74	4.38 %	Quarterly
1995-04-07	1995-05-01	0.74	4.72 %	Quarterly
1995-01-06	1995-02-01	0.74	5.06 %	Quarterly
1994-10-07	1994-11-01	0.73	5.13 %	Quarterly
1994-07-01	1994-08-01	0.73	5.41 %	Quarterly
1994-04-01	1994-05-01	0.73	5.59 %	Quarterly
1994-01-07	1994-02-01	0.73	5.02 %	Quarterly
1993-10-01	1993-11-01	0.72	5.03 %	Quarterly
1993-07-02	1993-08-01	0.72	4.88 %	Quarterly
1993-04-02	1993-05-01	0.72	4.84 %	Quarterly
1993-01-08	1993-02-01	0.72	4.20 %	Quarterly
1992-10-02	1992-11-01	0.69	4.40 %	Quarterly
1992-07-03	1992-08-01	0.69	4.10 %	Quarterly
1992-04-03	1992-05-01	0.69	3.30 %	Quarterly
1992-01-03	1992-02-01	0.69	2.93 %	Quarterly
1991-10-04	1991-11-01	0.60	2.90 %	Quarterly
1991-07-05	1991-08-01	0.60	3.00 %	Quarterly
1991-04-05	1991-05-01	0.60	2.94 %	Quarterly
1991-01-04	1991-02-01	0.60	3.28 %	Quarterly
1990-10-05	1990-11-01	0.53	3.49 %	Quarterly
1990-07-06	1990-08-01	0.53	3.30 %	Quarterly
1990-04-06	1990-05-01	0.53	3.87 %	Quarterly
1990-01-05	1990-02-01	0.53	3.62 %	Quarterly
1989-09-25	1989-11-01	0.50	4.06 %	Quarterly
1989-07-07	1989-08-01	0.50	4.01 %	Quarterly
1989-04-07	1989-05-01	0.50	3.91 %	Quarterly
1989-01-06	1989-02-01	0.50	3.89 %	Quarterly
1988-10-07	1988-11-01	0.42	3.82 %	Quarterly
1988-07-01	1988-08-01	0.42	4.05 %	Quarterly
1988-03-31	1988-05-01	0.42	3.65 %	Quarterly
1988-01-08	1988-02-01	0.42	3.40 %	Quarterly
1987-10-02	1987-11-01	0.35	2.73 %	Quarterly
1987-07-03	1987-08-01	0.35	2.58 %	Quarterly
1987-04-03	1987-05-01	0.70	2.49 %	Quarterly
1987-01-02	1987-02-01	0.70	2.67 %	Quarterly
		0.55	2.82 %	Quarterly
		0.55	2.23 %	Quarterly
		0.47	2.86 %	Quarterly
		0.47	3.35 %	Quarterly
		0.47	2.84 %	Quarterly
		0.47	2.90 %	Quarterly
		0.40	3.06 %	Quarterly
		0.40	3.34 %	Quarterly
		0.40	2.98 %	Quarterly
		0.40	2.83 %	Quarterly
		0.30	2.84 %	Quarterly
		0.30	2.71 %	Quarterly
		0.30	2.76 %	Quarterly
		0.60	3.08 %	Quarterly
		0.53	3.13 %	Quarterly
		0.53	3.25 %	Quarterly
		0.53	3.61 %	Quarterly
		0.53	3.35 %	Quarterly
		0.46	4.24 %	Quarterly
		0.46	3.49 %	Quarterly
		0.46	3.60 %	Quarterly
		0.40	3.13 %	Quarterly
		0.46	2.35 %	Irregular
		0.40	3.31 %	Quarterly
		0.40	3.91 %	Quarterly
		0.40	4.63 %	Quarterly
		0.36	3.86 %	Quarterly
		0.36	3.90 %	Quarterly
		0.36	4.12 %	Quarterly
		0.36	3.74 %	Quarterly
		0.30	3.41 %	Quarterly
		0.30	3.50 %	Quarterly
		0.30	3.24 %	Quarterly
		0.30	3.78 %	Quarterly
		0.28	3.27 %	Quarterly
		0.28	2.99 %	Quarterly
		0.28	3.15 %	Quarterly
		0.55	3.05 %	Quarterly
		0.45	2.61 %	Quarterly
		0.45	2.42 %	Quarterly
		0.45	2.23 %	Quarterly
		0.45	2.31 %	Quarterly
		0.45	2.35 %	Quarterly
		0.40	2.58 %	Quarterly
		0.40	2.30 %	Quarterly
		0.40	2.63 %	Quarterly
		0.38	3.10 %	Quarterly
		0.38	4.52 %	Quarterly
		0.38	2.76 %	Quarterly
		0.38	2.79 %	Quarterly
		0.33	2.91 %	Quarterly
		0.33	2.13 %	Quarterly
		0.33	1.89 %	Quarterly
		0.33	1.92 %	Quarterly
		0.30	1.31 %	Quarterly
		0.30	0.88 %	Quarterly
		0.30	0.47 %	Quarterly

Recent News

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026.

2026-06-18 06:59:00

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.

2026-06-17 16:16:00

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMY--Mariska Hargitay Partners with BMS for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease.

2026-06-08 06:59:00

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company's investigational small-molecule HIF-2a inhibitor, to be eval.

2026-06-03 08:00:00

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival.

2026-06-02 08:00:00

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--US FDA Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM.

2026-06-01 06:59:00

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #HodgkinLymphoma--BMS Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma.

2026-06-01 06:55:00

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in.

2026-05-29 08:00:00

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.

2026-05-27 06:59:00

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline.

2026-05-21 17:01:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions